Table 2 Comparison of clinical outcomes between STER and ESE
Clinical outcomes | STER | ESE | P value |
|---|---|---|---|
Number of lesions | 44 | 50 | |
Complete resection (%) | 100 | 92 | < 0.05 |
Mean procedure time, min (range) | 104.9000 ± 49.59105 (37.00–185.00) | 69.4000 ± 39.68344 (29.00–160.00) | < 0.05 |
Histology diagnosis (%) | |||
Leiomyoma | 31 (70.45) | 34 (68.00) | |
Spindle cell type tumors (Immunohistochemical staining showed leiomyoma) | 3 (6.82) | 0 | |
GIST | 10 (22.72) | 14 (28.00) | |
Very low malignant | 4 (9.09) | 0 | |
Low malignant | 6 (13.64) | 8 (16.00) | |
Intermediate malignant | 0 | 6 (12.00) | |
Schwannoma | 2 (4.54) | 2 (4.00) | |
Lipoma | 1 (2.27) | 0 | |
Complications (%) | 22 | 8 | < 0.05 |
Subcutaneous emphysema | 12 (54.55) | 2 (25.00) | |
Mediastinal emphysema | 0 | 0 | |
Pneumothorax | 6 (27.27) | 2 (25.00) | |
Pneumoperitoneum | 2 (9.09) | 0 | |
Hemorrhage | 0 | 2 (25.00) | |
Perforation | 0 | 0 | |
Nasal bleeding | 2 (9.09) | 0 | |
Delayed bleeding | 0 | 0 | |
Fever | 0 | 2 (25.00) | |
Median follow-up period, month (range) | 17.5250 ± 14.3169 (6.00–48.00) | 11.9600 ± 6.5371 (3.00–24.00) | |
Tumor recurrence | 0 | 0 | NSa |